17 September 2024 - BioCryst Pharmaceuticals today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for oral, once daily Orladeyo (berotralstat), which is approved in Canada for the routine prevention of attacks of hereditary angioedema in adults and paediatric patients 12 years of age and older.
Orladeyo was approved by Health Canada in June 2022.